Albinism and genetics

• Definition: Albinism is the absence of pigment such as melanin in eyes, skin, hair, scales, or feathers. It is a direct result of decreased or nonexistent pigmentation of the skin, hair, and eyes.

Risk Factors

Tyrosine, an amino acid, is normally converted by the enzyme tyrosinase to a variety of pigments called “melanins,” which give an organism its characteristic colors in areas such as the skin, hair, and eyes. Albinism results when the body cannot produce melanin because of defects in tyrosine metabolism. Oculocutaneous albinism includes multiple types, including tyrosinase-negative OCA1A, which describes the complete absence of tyrosinase activity, and tyrosinase-positive OCA1B, which is characterized by reduced tyrosinase activity. The most serious case is that of complete albinism or tyrosinase-negative oculocutaneous albinism, in which pigment is absent.

Etiology and Genetics

Albinism appears in various forms and may pass to offspring through autosomal recessive, autosomal dominant, or X-linked modes of inheritance. In the autosomal recessive case, both parents of a child with autosomal recessive albinism are carriers—that is, they each have one copy of the recessive form of the gene and, therefore, do not have the condition themselves. When both parents are carriers, there is a one-in-four chance that the child will inherit the condition. On the other hand, X-linked albinism occurs almost exclusively in males, and mothers who carry the gene will pass it on 50 percent of the time. Oculocutaneous albinism (OCA), the most common type, usually results from a mutation in one of eight genes from OCA1 to OCA8. Ocular albinism is associated with a gene change on the X chromosome.

Symptoms

People with this condition may have white hair, colorless skin, red irises, and serious vision impairments. The red irises are caused by the lack of pigmentation in the retina and subsequent light reflection from the blood in the retina. These people may also display rapid eye movements (nystagmus) and suffer from photophobia, and decreased visual acuity. People with this disorder sunburn easily since their skin does not tan. Partial albinism, sometimes called “piebaldism,” is characterized by the patchy absence of pigment in places like the hair, forehead, elbows, and knees, usually resulting from mutations in the KIT proto-oncogene.

Ocular albinism is inherited and involves the lack of melanin only in the eye, while the rest of the body shows normal or near-normal coloration. This condition reduces visual acuity from 20/60 to 20/400, with African Americans occasionally showing acuity as good as 20/25. Other problems include strabismus (crossed eyes or squint), sensitivity to brightness, and nystagmus.

Several complex diseases are associated with albinism. Waardenburg syndrome is identified by the presence of a white forelock (a lock of hair that grows on the forehead) or the absence of pigment in one or both irises, Chediak-Higashi syndrome is characterized by a partial lack of pigmentation of the skin, and patients with tuberous sclerosis have only small, localized depigmented areas. A more serious associated condition is Hermansky-Pudlak syndrome, a syndromic form of albinism that includes a bleeding tendency. Griscelli syndrome, Tietz syndrome, Waardenburg syndrome, and Vici syndrome are also associated with albinism.

Screening and Diagnosis

A physical examination will reveal the nature and extent of albinism. In ocular albinism, the color of the iris may be any of the normal colors, but an ophthalmologist can detect the condition by examining the eye.

Treatment and Therapy

Albinism can affect an individual’s lifestyle. Treatment of the disease involves reduction of the discomfort the sun creates. Thus, photophobia may be relieved by sunglasses that filter ultraviolet light, while sunburn may be reduced by the use of sun protection factor (SPF) sunscreens and by covering the skin with clothing.

In ocular albinism, the light shines through the iris because of the absence of the light-absorbing pigment. Children with this condition have difficulty reading what is on the board in school unless they are very close to it. Surgery and the application of optical aids have had positive results in correcting such problems. In 2026, ClinicalTrials.gov listed a trial of JWK010 gene therapy for oculocutaneous albinism type 1, reflecting continued investigation into gene-based treatment approaches for albinism.

Prevention and Outcomes

Albinism has long been studied in humans and captive animals. Since albinism is basically an inherited condition, genetic counseling is of great value to individuals with a family history of albinism. Albinism has not been found to affect expected life span among humans, but it does increase one’s susceptibility to sunburns and skin cancer.

Albinism occurs in wild animals, but such animals often have little chance of survival because they cannot develop normal camouflage colors, which are important for protection from predators. Animals in which albinism has been recorded include deer, giraffes, squirrels, frogs, parrots, robins, turtles, trout, crocodiles, alligators, and lobsters. Partial albinism has also been reported in wildlife. In other cases, such as the black panther of Asia, too much melanin forms due to the inheritance of a recessive allele, causing a condition called “melanism.”

Albinism has also been observed in plants, but their life span rarely goes beyond the seedling state because without the green pigment chlorophyll, they cannot obtain energy using photosynthesis. A few species of plants, such as ghost plants (Monotropa uniflora), are normally albino and obtain their energy and nutrition from decaying material in the soil.

Bibliography

“Albinism.” MedlinePlus, U.S. National Library of Medicine, 31 Dec. 2023, medlineplus.gov/ency/article/001479.htm. Accessed 16 May 2026.

“Albinism.” National Health Service, 26 Sept. 2023, www.nhs.uk/conditions/albinism. Accessed 16 May 2026.

Federico, Justin R., and Karthik Krishnamurthy. “Albinism.” StatPearls, National Library of Medicine, 14 Aug. 2023, www.ncbi.nlm.nih.gov/books/NBK519018. Accessed 16 May 2026.

Gahl, W. A., et al. “Genetic Defects and Clinical Characteristics of Patients with a Form of Oculocutaneous Albinism (Hermansky-Pudlak Syndrome).” The New England Journal of Medicine, vol. 338, no. 18, 1998, pp. 1258–64.

Gershoni-Baruch, R., et al. “Dopa Reaction Test in Hair Bulbs of Fetuses and Its Application to the Prenatal Diagnosis of Albinism.” Journal of the American Academy of Dermatology, vol. 24, no. 2 Pt 1, 1991, pp. 220–22.

King, Richard A., et al. “Albinism.” The Online Metabolic and Molecular Bases of Inherited Disease, edited by David L. Valle et al., McGraw-Hill Education, 2019, doi:10.1036/ommbid.256. Accessed 16 May 2026.

King, Richard A., and C. Gail Summers. “Albinism: Ocular and Oculocutaneous and Hermansky-Pudlak Syndrome.” Management of Genetic Syndromes, edited by Suzanne B. Cassidy and Judith E. Allanson. 3rd ed., Wiley, 2010, pp. 53–68.

“Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects with Oculocutaneous Albinism Type 1 (OCA1).” ClinicalTrials.gov, National Library of Medicine, 2026, clinicaltrials.gov/study/NCT07313618. Accessed 16 May 2026.

Salway, Jack G. “Amino Acid Disorders: Maple Syrup Urine Disease, Homocystinuria, Alkaptonuria, and Albinism.” Medical Biochemistry at a Glance. 3rd ed., Blackwell, 2012, pp. 102–4.